HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained a Buy rating for SpringWorks Therapeutics (NASDAQ:SWTX) but lowered its price target from $58.00 to $52.00. Despite the reduction in the price target, the new target suggests a significant upside of 133.18% from the current trading price of $22.30. SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for rare diseases and cancer.
November 20, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on SpringWorks Therapeutics with a lowered price target of $52, suggesting a potential upside of 133.18% from the current price.
The maintenance of a Buy rating by HC Wainwright & Co. indicates a positive outlook on SpringWorks Therapeutics, which could instill investor confidence and drive short-term interest in the stock. The lowered price target, while still representing a significant upside, may reflect a more conservative valuation by the analyst firm. Given the current trading price and the potential for a substantial increase, this news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100